Open AccessBiological treatment of severe asthma: new objectives and new treatment options
Author(s) -
Natalia Nenasheva
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-15-50-61
Subject(s) - dupilumab , tolerability , atopic dermatitis , asthma , medicine , monoclonal antibody , immunology , inflammation , pathogenesis , proinflammatory cytokine , monoclonal , antibody , adverse effect
This article is devoted to the main characteristics of severe bronchial asthma (SBA) and its heterogeneity, in particular, T2 asthma is characterized and the role of the main cytokines forming T2-inflammation is presented. The main emphasis is made on the role of the IL-4 and IL-13 in the pathogenesis of AD as the key cytokines in the initiation and maintenance of T2-inflammation, as well as on a new biological molecule – monoclonal antibody – dupilumab, directed to the α-subunit of IL-4 receptor, thus blocking the pathways of IL-4 and IL-13. Dupilumab has recently been registered in our country for the treatment of moderate and severe BA, as well as moderate and severe atopic dermatitis. The article presents the clinical efficacy and tolerability of dupillumab in patients with moderate and severe BA.